KISII, Kenya, Oct 23 – The U.S Food and Drug Administration ( FDA) has confirmed the availability of lenacapavir, a two yearly injectable HIV/ADS treatment as early as summer 2025, a decision made by ...

The treatment combines MSD’s islatravir with Gilead’s lenacapavir. Credit: Ground Picture via Shutterstock. Gilead Sciences and MSD are advancing their once-weekly HIV treatment regimen to Phase II ...

Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational combination of islatravir and lenacapavir for the treatment of HIV.

lenacapavir reduced HIV infections by 96% ... The most common side effect was the formation of harmless subcutaneous nodules, which typically decreased with subsequent injections.

In this open-label, active-controlled study, virologically suppressed adults on Biktarvy were randomly allocated in a 1:1 ratio to receive either oral islatravir 2 mg and lenacapavir 300 mg once a ...

Along with these most recent study results, the potent antiviral activities, and pharmacokinetic profiles of islatravir and lenacapavir support their continued development as an investigational ...

But in terms of HIV preventions, there is already another groundbreaking drug called lenacapavir. The anti-HIV compound is already in use, but getting the drug to those who need it most could ...

In June 2024, Gilead released data from the Phase III PURPOSE 1 study, announcing that its investigational PrEP shot lenacapavir showed 100% efficacy in preventing HIV in cisgender women. Gilead ...

But will doctors use it? In its push to gain approval for its long-acting answer lenacapavir, Gilead also has reported stellar results from two phase 3 trials including the PURPOSE 1 study ...